223nok
-1,8 %
Date:2024-11-22Time:12:31:40Latest report:Q3-2024List:Oslo BorsTicker:ULTI
Market Cap:77 mnokEnterprise Value:-52 mnokNet Sales:- mnokEarnings:-149,3 mnokEmployees:0ISIN:NO0010851603

Ratios

10-year key figure history for Ultimovacs turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Ultimovacs with index and moving average MA50 and MA200.

Stockprice:2,18
MA50:1,81
MA200:18,60
Price/MA200:-88,3 %
RSI (14):64,0
Price/MA50:20,5 %

Description

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Pharmaceuticals